Randomized comparison of SBRT vs RFA for recurrent small HCC
Matthias Guckenberger, Radiation Oncologist at University Hospital Zurich, shared a recent article by Mian Xi on X:
“Randomized comparison of SBRT vs RFA for recurrent Small Hepatocellular Carcinoma (n=166 patients).
– Freedom from local progression significantly improved after SBRT: 2a 92.7% vs 75.8%, HR=0.45.
– No difference in PFS (median 37.6 vs 27.6mo) and OS (2a 97.6% vs 93.9%).
Authors: Mian Xi, Zhoutian Yang, Li Hu, Yizhen Fu, Dandan Hu, Zhongguo Zhou, Mengzhong Liu, Jing Zhao, Jingxian Shen, Qiaoqiao Li, Baoqing Chen, Li Xu, Aiping Fang, Minshan Chen, Shiliang Liu and Yaojun Zhang
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, also shared the post on X:
“The heavy lifting now begins to discuss these data with interventional radiologists – including those who call themselves interventional oncologists – and review why CT-based dosimetry matters.”
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
More posts featuring Matthias Guckenberger.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023